Cancer targeting using carbonic anhydrase isoform IX inhibitors
US8980932B2 · kind B2 · utility
0Cited by
2References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 21, 2011 |
| Grant date | Mar 17, 2015 |
| Priority date | — |
| Expiry date | Dec 21, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D233/95
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns novel carbonic anhydrase IX inhibitors comprising a nitroimidazole moiety and their use in therapy of hypoxic conditions, in particular cancer treatment, especially chemotherapy and radiotherapy. The compounds of the invention have an increased specificity for the carbonic anhydrase IX enzyme compared to the art. The present invention relates to novel nitroimidazole derivates represented by formula (1).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.